Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1469438
This article is part of the Research Topic Pharmacogenomics for Improving Drug Safety and Efficacy in Cancer View all 8 articles

Response to trastuzumab deruxtecan (DS-8201) and delayed immunerelated events in a patient with metastatic HER2-positive NSCLC: a case report and literature review

Provisionally accepted
Lu Wang Lu Wang 1Shidi Wen Shidi Wen 1*Wenjia Zhu Wenjia Zhu 1,2Zhiyang Zhang Zhiyang Zhang 1,3*Yuejuan Cheng Yuejuan Cheng 1,3*
  • 1 Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng, Beijing Municipality, China
  • 2 Peking Union Medical College Hospital (CAMS), Beijing, Beijing Municipality, China
  • 3 Department of Medical Oncology, Peking Union Medical College Hospital (CAMS), Beijing, Beijing, China

The final, formatted version of the article will be published soon.

    Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate (ADC) designed to target HER2 mutations. We reported a case study demonstrating a favorable response to DS-8201 in a patient with HER2 mutation-positive non-small cell lung cancer (NSCLC) who exhibited resistance to initial immunotherapy, along with delayed immune-related events of hypoadrenocorticism occurring five months after discontinuation of immune checkpoint inhibitors. After reviewing the relevant literature, we discussed the mechanism of ADC agents underlying their anti-tumor activity and the potential impact of DS-8201 on the tumor microenvironment. This case highlights the efficacy of DS-8201 in NSCLC, particularly in individuals who have failed first-line immunotherapy, and provide valuable insights for clinicians exploring innovative strategies for the management of patients with lung cancer.

    Keywords: Antibody-drug conjugate, trastuzumab deruxtecan, Immune-related adverse events, lung cancer, case report

    Received: 23 Jul 2024; Accepted: 24 Dec 2024.

    Copyright: © 2024 Wang, Wen, Zhu, Zhang and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Shidi Wen, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng, 100006, Beijing Municipality, China
    Zhiyang Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng, 100006, Beijing Municipality, China
    Yuejuan Cheng, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongcheng, 100006, Beijing Municipality, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.